Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)
26 sept. 2024 01h00 HE
|
Pharming Group N.V.
For media and investors only Indicated for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Leiden, the...
Pharming Group to participate in September investor conferences
04 sept. 2024 01h00 HE
|
Pharming Group N.V.
Leiden, the Netherlands, September 4, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor...
Pharming Group reports second quarter and first half 2024 financial results and provides business update
01 août 2024 01h00 HE
|
Pharming Group N.V.
Second quarter 2024 total revenues increased by 35% to US$74.1 million, compared to the second quarter 2023, driven by strong RUCONEST® and Joenja® revenue growthRUCONEST® second quarter revenue...
Pharming Group to report second quarter and first half 2024 financial results on August 1
18 juil. 2024 02h00 HE
|
Pharming Group N.V.
Leiden, the Netherlands, July 18, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) second quarter and first half 2024...
Pharming Group to participate in June investor conferences
03 juin 2024 02h00 HE
|
Pharming Group N.V.
Leiden, the Netherlands, June 3, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor...
Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union
30 mai 2024 16h44 HE
|
Pharming Group N.V.
Leiden, the Netherlands, May 30, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today an update on the ongoing review of its Marketing...
Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders
21 mai 2024 11h30 HE
|
Pharming Group N.V.
Leiden, the Netherlands, May 21, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM/Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today,...
Pharming Group to participate in May investor conference
20 mai 2024 02h00 HE
|
Pharming Group N.V.
Leiden, the Netherlands, May 20, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor...
Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025
15 mai 2024 01h00 HE
|
Pharming Group N.V.
THIS NOTICE IS IMPORTANT AND REQUIRES THE IMMEDIATE ATTENTION OF BONDHOLDERS. IF BONDHOLDERS ARE IN ANY DOUBT AS TO THE ACTION THEY SHOULD TAKE, THEY SHOULD SEEK THEIR OWN FINANCIAL AND LEGAL ADVICE...
Pharming Group reports first quarter 2024 financial results and provides business update
08 mai 2024 01h00 HE
|
Pharming Group N.V.
First quarter 2024 revenues increased by 31% to US$55.6 million, compared to the first quarter 2023, driven by the U.S. commercial launch of Joenja® and revenue growth of RUCONEST®RUCONEST® revenues...